ConductScience.org, home

Gene · 8808

IL36R: interleukin 36 receptor

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. IL36R: interleukin 36 receptor. Genes, record 8808. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/8808

On this page

Gene

Symbol
IL36R
HGNC
Name
interleukin 36 receptor
HGNC
NCBI Gene ID
8808
NCBI Gene
HGNC ID
HGNC:5999
HGNC
Ensembl
ENSG00000115598
NCBI Gene
Aliases
IL-1Rrp2, IL-36R, IL1R-rp2, IL1RL2, IL1RRP2
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q9HB29Interleukin-1 receptor-like 25753Ensembl, GeneID, HGNC

Source UniProt

Patents71

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
EP 4757832 A12026-06-174Q9HB29Espacenet
JP 2026506716 A2026-02-251Q9HB29Espacenet
JP 2026004568 A2026-01-1450145Q9HB29Espacenet
JP 2026004568 A2026-01-1450148Q9HB29Espacenet
EP 4671282 A12025-12-311Q9HB29Espacenet
JP 2025172069 A2025-11-20223Q9HB29Espacenet
EP 4650780 A22025-11-192330Q9HB29Espacenet
US 12471579 B22025-11-182Q9HB29Espacenet
EP 4641201 A22025-10-291892Q9HB29Espacenet
KR 1020250153801 A2025-10-271Q9HB29Espacenet

1 to 10 of 71

See all 71 patents

Drugs2

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
IMSIDOLIMABCHEMBL4650441IL36 receptor antagonistANTAGONISTChEMBL
SPESOLIMABCHEMBL4297911IL36 receptor antagonistANTAGONISTChEMBL

Trials33

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT06886009SPESOLIMABClinicalTrials.gov
NCT06624670SPESOLIMABPHASE3ClinicalTrials.gov
NCT06241573SPESOLIMABPHASE2/PHASE3ClinicalTrials.gov
NCT06092216SPESOLIMABPHASE2ClinicalTrials.gov
NCT05856526SPESOLIMABPHASE2/PHASE32026-03-12ClinicalTrials.gov
NCT05819398SPESOLIMABPHASE2/PHASE32025-11-05ClinicalTrials.gov
NCT05670821SPESOLIMABClinicalTrials.gov
NCT05366855IMSIDOLIMABPHASE3ClinicalTrials.gov
NCT05352893IMSIDOLIMABPHASE32026-03-17ClinicalTrials.gov
NCT05239039SPESOLIMABPHASE32024-10-09ClinicalTrials.gov

1 to 10 of 33

See all 33 trials

NIH grants644

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleIL36R papersNewest fiscal year
R01AI015614Pathogenesis of Fever in Man82025
ZIDAR041180Clinical Support Services for the NIAMS Intramural Research Program42025
ZIAAI001220Pathogenesis, and Outcome of Autoinflammatory Diseases, NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still's-like Diseases, and other Undifferentiated Autoinflammatory Diseases32025
ZIEAR041176Clinical Training in Rheumatology32025
P30AR075043University of Michigan Skin Biology and Diseases Resource-based Center22025
P30CA072720Cancer Center Support Grant22025
P30DK097948The Cleveland Digestive Diseases Research Core Center (DDRCC)22025
P30EY003790Core Grant for Vision Research22025
P30EY004068Core Grant for Vision Research22025
R01AI163029Inborn errors of immunity in patients with life-threatening COVID-1922025

1 to 10 of 644Source NIH's project files

See all 644 nih grants

Papers947

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
An Evolving Landscape in GPP Management: Recibokibart and the Prospect of Broader Access to IL-36 Receptor Blockade.Br J Dermatol202642710062PubTator, text miningPubMed
Japanese intractable and rare dermatologic diseases: From the official skin-centered nanbyo core to an illustrative mechanism-based framework.Intractable Rare Dis Res202642643679PubTator, text miningPubMed
Author Correction: IL-17D-induced inhibition of DDX5 expression in keratinocytes amplifies IL-36R-mediated skin inflammation.Nat Immunol202642608477PubTator, text miningPubMed
Effectiveness and Safety of Spesolimab in Adolescents and Adults with Generalized Pustular Psoriasis.Pragmat Obs Res202642604245PubTator, text miningPubMed
INDIVIDUAL ARTICLE: Generalized Pustular Psoriasis: A Contemporary Review of Diagnosis, Pathophysiology, and IL-36 Pathway-Directed Management.J Drugs Dermatol202642555081PubTator, text miningPubMed
When Conventional Therapy Fails: Interleukin-36 Inhibition for Severe Hydroxychloroquine-Induced Acute Generalized Exanthematous Pustulosis in Systemic Lupus Erythematosus - A Case Report.Case Rep Dermatol202642524626PubTator, text miningPubMed
Mitochondrial and Epigenetic Drivers of Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease.Antioxidants (Basel)202642510568PubTator, text miningPubMed
A review of core immuno-inflammatory mechanisms and key regulatory targets in psoriasis.Am J Clin Exp Immunol202642487722PubTator, text miningPubMed
Management of Generalized Pustular Psoriasis Flare with Intravenous Spesolimab Followed by Long-Term Treatment with Subcutaneous Spesolimab: A Case Report.Case Rep Dermatol202642396388PubTator, text miningPubMed
IL-36-Driven Inflammation in Generalized Pustular Psoriasis: Immunological Insights from Plaque Psoriasis and Implications for Targeted Therapy.Int J Mol Sci202642196416PubTator, text miningPubMed

1 to 10 of 947

See all 947 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/8808

GET https://conductscience.org/api/genes/v1/8808/patents?page=2